HAP Trading’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $339K | Buy |
22,000
+7,900
| +56% | +$5.88M | 0.02% | 313 |
|
|
2025
Q2 | $343K | Buy |
+14,100
| New | +$11M | 0.03% | 242 |
|
|
2025
Q1 | – | Sell |
-33,700
| Closed | -$1.11M | – | 809 |
|
|
2024
Q4 | $1.11M | Buy |
33,700
+4,000
| +13% | +$3.31M | 0.1% | 120 |
|
|
2024
Q3 | $767K | Sell |
29,700
-5,800
| -16% | -$5.21M | 0.09% | 143 |
|
|
2024
Q2 | $585K | Buy |
35,500
+14,200
| +67% | +$11.4M | 0.07% | 174 |
|
|
2024
Q1 | $93.3K | Sell |
21,300
-900
| -4% | -$641K | 0.01% | 362 |
|
|
2023
Q4 | $101K | Buy |
22,200
+7,500
| +51% | +$4.38M | 0.02% | 367 |
|
|
2023
Q3 | $208K | Buy |
14,700
+1,700
| +13% | +$876K | 0.03% | 305 |
|
|
2023
Q2 | $27.2K | Buy |
13,000
+2,000
| +18% | +$839K | ﹤0.01% | 630 |
|
|
2023
Q1 | $151K | Sell |
11,000
-9,800
| -47% | -$3.31M | 0.02% | 345 |
|
|
2022
Q4 | $37K | Buy |
20,800
+1,300
| +7% | +$461K | ﹤0.01% | 809 |
|
|
2022
Q3 | $93K | Buy |
19,500
+1,300
| +7% | +$412K | 0.01% | 813 |
|
|
2022
Q2 | $75K | Buy |
+18,200
| New | +$5.46M | ﹤0.01% | 958 |
|
|
2022
Q1 | – | Sell |
-11,300
| Closed | -$48K | – | 2547 |
|
|
2021
Q4 | $48K | Sell |
11,300
-700
| -6% | -$177K | ﹤0.01% | 1503 |
|
|
2021
Q3 | $90K | Sell |
12,000
-4,600
| -28% | -$1.14M | ﹤0.01% | 1281 |
|
|
2021
Q2 | $67K | Sell |
16,600
-7,400
| -31% | -$1.49M | ﹤0.01% | 1363 |
|
|
2021
Q1 | $214K | Buy |
24,000
+10,100
| +73% | +$1.98M | 0.01% | 744 |
|
|
2020
Q4 | $20K | Buy |
13,900
+500
| +4% | +$74.7K | ﹤0.01% | 1701 |
|
|
2020
Q3 | $63K | Sell |
13,400
-122,600
| -90% | -$19M | ﹤0.01% | 911 |
|
|
2020
Q2 | $340K | Buy |
136,000
+121,000
| +807% | +$18.6M | 0.02% | 537 |
|
|
2020
Q1 | $47K | Buy |
+15,000
| New | +$2.06M | ﹤0.01% | 785 |
|
|
2019
Q4 | – | Sell |
-59,600
| Closed | -$152K | – | 1370 |
|
|
2019
Q3 | $152K | Buy |
59,600
+4,300
| +8% | +$479K | 0.01% | 550 |
|
|
2019
Q2 | $276K | Sell |
55,300
-574,000
| -91% | -$67.6M | 0.02% | 445 |
|
|
2019
Q1 | $490K | Buy |
+629,300
| New | +$76.5M | 0.04% | 288 |
|
|
2018
Q4 | – | Sell |
-165,900
| Closed | -$4K | – | 1222 |
|
|
2018
Q3 | $4K | Buy |
+165,900
| New | +$16.6M | ﹤0.01% | 926 |
|
|
2017
Q2 | – | Sell |
-10,600
| Closed | -$7K | – | 1075 |
|
|
2017
Q1 | $7K | Sell |
10,600
-81,200
| -88% | -$6.5M | ﹤0.01% | 943 |
|
|
2016
Q4 | $331K | Sell |
91,800
-102,100
| -53% | -$7.6M | 0.02% | 404 |
|
|
2016
Q3 | $38K | Buy |
193,900
+182,200
| +1,557% | +$14.6M | ﹤0.01% | 747 |
|
|
2016
Q2 | $21K | Sell |
11,700
-2,000
| -15% | -$151K | ﹤0.01% | 713 |
|
|
2016
Q1 | $106K | Sell |
13,700
-5,500
| -29% | -$416K | 0.01% | 447 |
|
|
2015
Q4 | $39K | Sell |
19,200
-5,100
| -21% | -$423K | ﹤0.01% | 670 |
|
|
2015
Q3 | $109K | Buy |
+24,300
| New | +$2.05M | 0.01% | 598 |
|
|
2015
Q2 | – | Sell |
-25,200
| Closed | -$4K | – | 1091 |
|
|
2015
Q1 | $4K | Sell |
25,200
-4,200
| -14% | -$299K | ﹤0.01% | 853 |
|
|
2014
Q4 | $64K | Buy |
+29,400
| New | +$1.98M | ﹤0.01% | 693 |
|
|
2014
Q1 | – | Sell |
-90,200
| Closed | -$5K | – | 1227 |
|
|
2013
Q4 | $5K | Sell |
90,200
-767,000
| -89% | -$38.4M | ﹤0.01% | 1081 |
|
|
2013
Q3 | $604K | Buy |
857,200
+756,200
| +749% | +$39.6M | 0.02% | 486 |
|
|
2013
Q2 | $234K | Buy |
+101,000
| New | +$5.5M | 0.01% | 640 |
|
Other funds holding LLY
HAP Trading's LLY Position: Q1 2025 in Review
HAP Trading sold out of Eli Lilly (LLY) in Q1 2025, closing a stake of 10,545 shares — an estimated $8.77M sold.
HAP Trading first reported a position in LLY in Q2 2013 and held it in 12 quarters. The position peaked at $17.2M in Q3 2016. 3,920 funds tracked by Wall St. Rank hold LLY as of Q1 2025.
- HAP Trading reported no remaining Eli Lilly position as of Q1 2025 after selling out during the quarter.
- HAP Trading sold 10,545 Eli Lilly shares in Q1 2025, an estimated $8.77M.
- HAP Trading first reported a position in Eli Lilly in Q2 2013 and held it in 12 quarters.
- HAP Trading's Eli Lilly position peaked at $17.2M in Q3 2016.
- 3,920 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2025.
Based on HAP Trading's 13F filing for Q1 2025, filed 14 May 2025.